Evidence map›Paper›PMID 41892820›Full record

SynthesisMedical sciences (Basel, Switzerland)2026

Survival Difference in Advanced-Stage Cervical and Ovarian Cancer Patients Treated with Concomitant Modulated Electro-Hyperthermia in Comparison to Classic Treatment Modalities: Results of a Pilot Study and Meta-Analysis.

Ivan Panczel, Magdolna Herold, Erika Borbenyi, Daniel Horanyi, Zoltan Novak, Magdolna Dank, Attila Marcell Szasz, Zoltan Herold

Abstract readMeta-AnalysisComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Medical sciences (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ivan PanczelDivision of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary.
Magdolna HeroldDivision of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary.ORCID 0000-0002-1036-6343
Erika BorbenyiDivision of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary.
Daniel HoranyiNational Institute of Oncology, H-1122 Budapest, Hungary.ORCID 0009-0006-2721-2240
Zoltan NovakNational Institute of Oncology, H-1122 Budapest, Hungary.
Magdolna DankDivision of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary.ORCID 0000-0002-4694-3624
Attila Marcell SzaszDivision of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary.
Zoltan HeroldDivision of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary.ORCID 0000-0001-5990-4889

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundModulated electro-hyperthermia (mEHT) is one of the latest advancements in the field of oncological hyperthermia. Previous studies investigating mEHT revealed that it is safe and effective; however, no meta-analysis was conducted either in cervical or ovarian cancer.

methodsA single-institute pilot case series and a meta-analysis were conducted. Advanced stage cervical and ovarian cancer cases were included. In the pilot study, mEHT treatments were conducted using the Oncotherm EHY-2000+ and the EHY-2030 devices with 2-3 treatment sessions per week.

resultsFor the meta-analysis, a total of five studies were identified, with 160 and 31 cervical and ovarian cancer patients, respectively. In addition, 175 standard-of-care-treated cervical cancer patients were also identified as controls. The 1- and 2-year survival rate of the cervical cancer patients treated with mEHT was 87.61% [95% confidence interval (CI): 71.31-100%] and 78.13% (95% CI: 53.02-100%). Compared to the controls, the 2-year survival rates (78.13% vs. 58.86%) were significantly better in the mEHT-treated cohorts (odds ratio: 0.4143,

conclusionsUsing mEHT, a significantly higher 2-year survival rate can be achieved in cervical cancer. In this setting, a wider testing/application of the modality is warranted. In the case of ovarian tumors, the available knowledge is minimal, and applicability and efficacy studies are urgently needed.

Indexed as

Hyperthermia, InducedOvarian NeoplasmsUterine Cervical NeoplasmsAdultFemaleHumansMiddle AgedNeoplasm StagingPilot ProjectsTreatment Outcomecervical cancerconcomitant therapymeta-analysismodulated electro-hyperthermiaovarian cancer

Identifiers

PMID41892820
PMCPMC13028291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.